Integrated multi-omics profiling identifies an immunotherapy vulnerable and prognostic associated subtype in Cholangiocarcinoma
Authors:
- Lu ChenLCLu Chen
- Yuchao HeYHYuchao He
- Hong SuHSHong Su
- Xiangdong TianXTXiangdong Tian
- Haotian LiaoHLHaotian Liao
- Dongming LiuDLDongming Liu
- Meng ZhaoMZMeng Zhao
- Huichuan SunHSHuichuan Sun
- Lisha QiLQLisha Qi
- Manqing CaoMCManqing Cao
- Zhiyong LiuZLZhiyong Liu
- Lin GuoLGLin Guo
Open Access
- 26 February 2026
- journal article
- research article
- Published by S. Karger AG in Liver Cancer
- p. 1-28
Abstract
Introduction: Cholangiocarcinoma (CCA) is an aggressive malignancy with poor prognosis and limited treatment options. Molecular heterogeneity and the tumor immune microenvironment play crucial roles in CCA progression and therapeutic response, but comprehensive stratification remains insufficient for guiding treatment decisions. Methods: This study performed integrated multi-omics profiling as well as immunohistochemical validation on 424 CCA patients. Multi-dimensional data, including genomic, epigenomic, transcriptomic, and immune profiling, were analyzed to identify clinically relevant molecular subtypes. Results: Four distinct molecular subtypes of CCA were identified, each exhibiting unique clinical and immunological features: C1 (Proliferation): Driven by TP53/KRAS mutations and CpG island methylator phenotype (CIMP+) hypermethylation, showing Th17 cells infiltration and poor outcomes; C2 (Immune-Suppressed Macro_LYVE1, (ISM_LYVE1)): Stroma-rich with LYVE1⁺ macrophages and epithelial-mesenchymal transition (EMT) activation; C3 (Immune-Activated Macro_C1QC (IAM_C1QC)): Enriched in C1QC⁺ macrophages, CD8⁺ T-cells, and metabolic pathways, highly responsive to immune checkpoint blockade (75% Overall Response Rate (ORR)); C4 (Immune Exclusion, (IE)): FGFR2-altered and IDH1-mutant, with an immunologically-cold phenotype. Conclusion: We validated ATP2B1 as a novel prognostic biomarker and developed a 160-gene classifier for subtype prediction. The C3 subtype’s exceptional immune checkpoint blockade (ICB) response, independent of conventional biomarkers (PD-L1/microsatellite instability (MSI)/tumor mutational burden (TMB)), highlights the clinical utility of this classification system in guiding precision immunotherapy for CCA.Keywords
This publication has 65 references indexed in Scilit:
- CholangiocarcinomaThe Lancet, 2014
- Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomasNature Genetics, 2013
- Regulation of Cell Proliferation and Migration by Keratin19-Induced Nuclear Import of Early Growth Response-1 in Breast Cancer CellsClinical Cancer Research, 2013
- Identification of Targetable FGFR Gene Fusions in Diverse CancersCancer Discovery, 2013
- Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factorsCancer Cell International, 2013
- The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinomaNature Reviews Gastroenterology & Hepatology, 2011
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- Interferon-α and cancer: Mechanisms of action and new perspectives of clinical useBiochimie, 2007
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (Review)International Journal of Molecular Medicine, 1998